

1 **Title** Human sperm TMEM95 binds eggs and facilitates membrane fusion

2

3 **Authors and Affiliations**

4 Shaogeng Tang<sup>a,b,1</sup>, Yonggang Lu<sup>d,e,1</sup>, Will M. Skinner<sup>h</sup>, Mrinmoy Sanyal<sup>a,b</sup>, Polina V.

5 Lishko<sup>i,j</sup>, Masahito Ikawa<sup>d,e,f,g,\*</sup>, Peter S. Kim<sup>a,b,c,\*</sup>

6

7 <sup>a</sup> Department of Biochemistry, Stanford University School of Medicine, Stanford, CA

8 94305

9 <sup>b</sup> Sarafan ChEM-H, Stanford University, Stanford, CA 94305

10 <sup>c</sup> Chan Zuckerberg Biohub, San Francisco, CA 94158

11 <sup>d</sup> Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan

12 <sup>e</sup> Department of Experimental Genome Research, Research Institute for Microbial

13 Diseases, Osaka University, Osaka 565-0871, Japan

14 <sup>f</sup> Center for Infectious Disease Education and Research, Osaka University, Osaka 565-

15 0871, Japan

16 <sup>g</sup> Laboratory of Reproductive Systems Biology, Institute of Medical Science, The

17 University of Tokyo, Tokyo 108-8639, Japan

18 <sup>h</sup> Endocrinology Graduate Group, University of California, Berkeley, Berkeley, CA 94720

19 <sup>i</sup> Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley,

20 CA 94720

21 <sup>j</sup> Center for Reproductive Longevity and Equality, Buck Institute for Research on Aging,

22 Novato, CA 94945

23 <sup>1</sup> S.T. and Y.L. contributed equally to this work

24 \* To whom correspondence may be addressed. Emails: P.S.K. [kimpeter@stanford.edu](mailto:kimpeter@stanford.edu),  
25 M.I. [ikawa@biken.osaka-u.ac.jp](mailto:ikawa@biken.osaka-u.ac.jp)

26

## 27 **Classification**

28 BIOLOGICAL SCIENCES - Developmental Biology

29 PHYSICAL SCIENCES - Biophysics and Computational Biology

30

## 31 **Keywords**

32 TMEM95, Membrane fusion, Sperm-egg fusion, Fertilization

33

## 34 **Abstract**

35 *Tmem95* encodes a sperm acrosomal membrane protein, whose knockout has a male-  
36 specific sterility phenotype in mice. How TMEM95 plays a role in membrane fusion of  
37 sperm and eggs has remained elusive. Here, we utilize a sperm penetration assay as a  
38 model system to investigate the function of human TMEM95. We show that human  
39 TMEM95 binds to hamster egg membranes, providing evidence for a TMEM95 receptor  
40 on eggs. Using X-ray crystallography, we reveal an evolutionarily conserved, positively  
41 charged region of TMEM95 as a putative receptor-binding surface. Amino-acid  
42 substitutions within this region of TMEM95 ablate egg-binding activity. We identify  
43 monoclonal antibodies against TMEM95 that reduce the number of human sperm fused  
44 with hamster eggs in sperm penetration assays. Strikingly, these antibodies do not  
45 block binding of sperm to eggs. Taken together, these results provide strong evidence

46 for a specific, receptor-mediated interaction of sperm TMEM95 with eggs and suggest  
47 that this interaction may have a role in facilitating membrane fusion.

48

## 49 **Significance statement**

50 Membrane fusion of sperm and eggs is pivotal in sexual reproduction. *Tmem95*  
51 knockout mice show male-specific sterility, but it was unknown how sperm TMEM95  
52 facilitates membrane fusion with eggs. We show here that human TMEM95 binds eggs.  
53 Our crystal structure of TMEM95 suggests a region where this binding may occur. We  
54 develop monoclonal antibodies against TMEM95 that impair sperm-egg fusion but do  
55 not block sperm-egg binding. Thus, we propose that there is a receptor-mediated  
56 interaction of sperm TMEM95 with eggs, and that this interaction may have a direct role  
57 in membrane fusion. Our work suggests avenues for the identification of the TMEM95  
58 egg receptor and may enable the development of infertility treatments and  
59 contraceptives for humans.

60

## 61 **Introduction**

62 Fertilization is a central event of sexual reproduction, but how sperm and eggs  
63 bind to and fuse with one another has been largely undefined. Sperm IZUMO1 (1) and  
64 egg JUNO (2) mediate the only known cell surface interaction between mammalian  
65 gametes. Recent reports suggested that *Tmem95* (encoding transmembrane protein  
66 95) mutant cattle exhibit impaired male fertility (3, 4); *Tmem95* knockout mice show  
67 male-specific sterility, producing sperm that can bind to, but do not fuse with eggs (5, 6).  
68 *Tmem95* encodes a sperm acrosomal membrane protein, which re-localizes to the

69 equatorial segment of the sperm head (3, 6) where membrane fusion with the egg takes  
70 place (7, 8). These observations shed light on a potential role of TMEM95 in sperm-egg  
71 membrane fusion.

72 Humans also express *TMEM95* transcripts (9). In this study, we utilized the  
73 sperm penetration assay (10), a clinical laboratory test that evaluates fusion of human  
74 sperm with eggs from Syrian golden hamsters (*Mesocricetus auratus*), as a model  
75 system. TMEM95 is a type-I single-pass transmembrane protein (3, 5, 6). Motivated by  
76 a hypothesis that the ectodomain of TMEM95 binds to eggs through a specific,  
77 membrane-bound receptor on eggs, we found that a bivalent TMEM95 ectodomain  
78 protein binds hamster eggs, providing direct evidence for a TMEM95 receptor on eggs.  
79 The 1.5 Å-resolution X-ray crystal structure of TMEM95 we describe here reveals an  
80 evolutionarily conserved region of the protein with a positively charged surface. Amino-  
81 acid substitutions within this region of TMEM95 ablate egg binding. We speculate that  
82 this region serves as an egg-receptor binding site for TMEM95.

83 We also found that human TMEM95 plays a role in membrane fusion. After  
84 generating two monoclonal antibodies that bind to different epitopes of TMEM95, we  
85 observed that neither antibody blocks binding of human sperm to hamster eggs, but  
86 both could inhibit membrane fusion of sperm with eggs. Taken together, our results  
87 provide evidence for a specific, receptor-mediated interaction of human sperm TMEM95  
88 with eggs and inform strategies for the identification of this receptor. We propose that  
89 the interaction of TMEM95 with eggs facilitates membrane fusion of human sperm and  
90 eggs.

## 91 **Results**

### 92 **A bivalent TMEM95 protein binds hamster eggs**

93 We hypothesized that the ectodomain of TMEM95 mediates a cell-surface  
94 interaction of sperm with eggs. To monitor the interaction between TMEM95 and eggs,  
95 we designed and produced TMEM95-Fc, a fusion protein of the ectodomain of human  
96 TMEM95 and the fragment crystallizable region of human immunoglobulin G1 (IgG1) (*SI*  
97 *Appendix*, Fig. S1A). TMEM95-Fc contains two copies of the TMEM95 ectodomain  
98 (Fig.1B) and the Fc confers increased avidity for binding over monomeric TMEM95.  
99 Given that human sperm can fuse with eggs from Syrian golden hamsters (10, 11), we  
100 incubated the Fc or TMEM95-Fc proteins with hamster eggs, whose surrounding zona  
101 pellucida and cumulus cells were removed. Using a fluorescently labeled anti-Fc  
102 antibody, we detected binding to the egg cell surface only with TMEM95-Fc, not Fc  
103 alone (Fig. 1A and B and *SI Appendix*, Fig. S1E). To confirm that our labeling approach  
104 can also detect known protein-protein interactions of sperm with eggs, we next  
105 surveyed IZUMO1-Fc on eggs, a fusion protein of sperm IZUMO1 (1) ectodomain with  
106 Fc. While IZUMO1-Fc binds eggs, the IZUMO1<sup>W148A</sup>-Fc variant does not (Fig. 1C and  
107 D). The substitution of W148A ablates the interaction of IZUMO1 with JUNO (*SI*  
108 *Appendix*, Fig. S1B-H) (12, 13), the egg receptor of IZUMO1 (2). Our results showed  
109 that TMEM95 binds egg plasma membranes and suggest the presence of a receptor for  
110 TMEM95 on eggs.

111

### 112 **The structure of TMEM95 is homologous to that of the N-terminus of**

### 113 **IZUMO1**

114 To understand how TMEM95 binds eggs, we determined a crystal structure of  
115 the TMEM95 ectodomain to 1.5 Å resolution using multi-wavelength anomalous X-ray  
116 diffraction (Fig. 2A and *SI Appendix*, Fig. S2A and Table S1). TMEM95 adopts an  
117 elongated rod shape, comprised of an N-terminal  $\alpha$ -helical bundle (residues 17-110)  
118 and a C-terminal  $\beta$ -hairpin region (residues 111-135) (Fig. 2C). TMEM95 shows  
119 homology to the N-terminus of IZUMO1 (12, 13) with a  $C_{\alpha}$  root-mean-square deviation  
120 of 7.2 Å, but TMEM95 does not share an immunoglobulin-like domain at the C-terminus  
121 with IZUMO1 (Fig. 2D). Unlike IZUMO1, the helical bundle of TMEM95 has three  
122 helices ( $\alpha 1$ ,  $\alpha 3$ , and  $\alpha 4$ ) and a coil (loop 2) that are arranged in an anti-parallel manner  
123 ( $\alpha 1$ -loop 2 and  $\alpha 3$ - $\alpha 4$ ). TMEM95 has three unique disulfide bonds: C35-C45 between  
124  $\alpha 1$  and loop 2 (*SI Appendix*, Fig. S2B), and C105-C134 and C109-C128 adjacent to the  
125  $\beta$ -hairpin (Fig. 2B-D).

126 JUNO does not act as an egg receptor for TMEM95 (5, 6). A conserved N-linked  
127 glycan in the  $\beta$ -hairpin of TMEM95 (*SI Appendix*, Fig. S2E and F) could cause a clash if  
128 TMEM95 were to make a contact similar to that of IZUMO1 with JUNO (*SI Appendix*,  
129 Fig. S2C and D). However, even if this glycan is removed by the treatment with N-  
130 glycosidase PNGaseF, TMEM95-Fc does not bind JUNO (*SI Appendix*, Fig. S2G and  
131 H).

132

### 133 **A conserved surface of TMEM95 is a putative receptor-binding site**

134 To gain further insights into the TMEM95 interaction with eggs, we analyzed the  
135 protein sequences of TMEM95 orthologs and mapped the degree of conservation for  
136 each amino acid onto the structure of TMEM95. We found that the area surrounding the

137 N-glycan is variable (Fig. 3A), while the opposite side harbors a conserved (Fig. 3B),  
138 positively charged surface (Fig. 3C).

139 To examine whether the conserved, charged surface is critical for binding of  
140 TMEM95 to eggs, we produced TMEM95-Fc proteins that carry amino-acid substitutions  
141 of arginine residues (Fig. 3D and *SI Appendix*, Fig. S3A). These TMEM95 variants have  
142 melting temperatures comparable to that of the wild-type TMEM95-Fc protein (*SI*  
143 *Appendix*, Fig. S3B). When incubated with hamster eggs, the R70A, R73A, and R70A  
144 R73A TMEM95-Fc variants showed drastically reduced egg-binding activities compared  
145 to the wild-type (Fig. 3E-H and *SI Appendix*, Fig. S3C). Our data suggest that the  
146 identified evolutionarily conserved, positively charged surface of TMEM95 may function  
147 as a receptor-binding site.

148

## 149 **Monoclonal antibodies detect TMEM95 in human sperm**

150 To generate reagents to investigate the functions of TMEM95 in human sperm,  
151 we immunized mice with the TMEM95 ectodomain (*SI Appendix*, Fig. S4A-C) and  
152 generated hybridoma cell lines that produce TMEM95 ectodomain-specific monoclonal  
153 antibodies, 3A01 and 6B08 (*SI Appendix*, Table S2). We used biolayer interferometry to  
154 assess the binding of the antibodies to TMEM95 (Fig. 4A) and found that 3A01 and  
155 6B08 bind TMEM95 via two non-competing epitopes (Fig. 4B) with association  
156 constants of 1.4 nM and 1.3 nM, respectively (*SI Appendix*, Fig. S4D and E). The  
157 binding of either 3A01 or 6B08 to TMEM95-Fc does not inhibit its binding to the eggs (*SI*  
158 *Appendix*, Fig. S4G). 3A01 and 6B08 bind similarly to TMEM95-Fc and the R70A and  
159 R73A TMEM95-Fc variants (*SI Appendix*, Fig. S4H). These results suggest that the

160 3A01 and 6B08 antibodies against TMEM95 do not compete for binding of TMEM95  
161 with its egg receptor.

162 We next performed Western blotting using the TMEM95 antibodies to probe  
163 whole cell lysates of human sperm and each could detect a band of ~20 kDa (*SI*  
164 *Appendix*, Fig. S4F), the expected molecular weight of TMEM95. To investigate whether  
165 TMEM95 is N-linked glycosylated, we treated the human sperm lysate with PNGaseF  
166 and observed a shift in size to ~17.5 kDa (Fig. 4C), consistent with the loss of one  
167 glycan. Our results show that TMEM95 is expressed and N-linked glycosylated in  
168 human sperm.

169 Using a similar approach for IZUMO1 (*SI Appendix*, Fig. S5A-C), we generated  
170 hybridoma cell lines that produce IZUMO1-specific monoclonal antibodies, 4E04 and  
171 6F02 (Fig. 4D and *SI Appendix*, Table S2). These antibodies both bind IZUMO1 (*SI*  
172 *Appendix*, Fig. S5F, S5J) via two non-competing epitopes (Fig. 4E and *SI Appendix*,  
173 Fig. S5D and E). Compared to 4E04-bound IZUMO1-Fc, 6F02-bound IZUMO1-Fc  
174 blocks binding of IZUMO1-Fc to eggs (*SI Appendix*, Fig. S5G) and JUNO (*SI Appendix*,  
175 Fig. S6H and I). These results suggest that 4E04 and 6F02 bind to different epitopes of  
176 IZUMO1, and that the 6F02 epitope overlaps with the IZUMO1-binding site for JUNO.

177

## 178 **TMEM95 antibodies impair fusion of human sperm to hamster eggs**

179 To examine whether human TMEM95 plays a role in membrane fusion, we  
180 produced the fragments antigen-binding (Fab) of the TMEM95 and IZUMO1 antibodies  
181 and tested these in a sperm penetration assay. These Fab fragments bind antigens at  
182 nanomolar affinities (*SI Appendix*, Figs. S4E and S5E) and may have less steric effects



183 in membrane fusion than their larger IgG counterparts. We inseminated hamster eggs  
184 with human sperm preincubated with the TMEM95 antibody Fab, 3A01 (Fig. 5C) or  
185 6B08 (Fig. 5D). We used an untreated group as a negative control (Fig. 5A) and  
186 IZUMO1 antibody Fab 6F02-treatment as a positive control (Fig. 5B). Based on the  
187 numbers of bound (Fig. 5E) and fused (Fig. 5F) sperm per egg, we found that the  
188 TMEM95 antibody Fab fragments do not block binding of sperm to eggs (Fig. 5E).

189         However, the averaged numbers of fused sperm per egg significantly decreased  
190 from  $9.1 \pm 0.7$  (mean  $\pm$  standard error of the mean, SEM) in the untreated group to  $4.1 \pm$   
191  $0.9$  ( $p = 0.0002$ ) and  $3.4 \pm 0.6$  ( $p < 0.0001$ ) in the TMEM95 Fab 3A01 and 6B08 groups,  
192 respectively (Fig. 5F and *SI Appendix*, Fig. S6A-D). Similarly, we observed that the  
193 TMEM95 antibody IgGs do not block sperm-egg binding (*SI Appendix*, Fig. S6E-G), but  
194 they decrease the average numbers of fused sperm per egg when compared with a  
195 control group treated with pre-immune IgG (*SI Appendix*, Fig. S6H-L). Therefore, the  
196 two non-competing TMEM95 monoclonal antibodies do not block sperm-egg binding but  
197 impair sperm-egg fusion, suggesting that TMEM95 plays a role in sperm-egg membrane  
198 fusion.

## 199 **Discussion**

### 200 **Evidence for a receptor for TMEM95 on eggs**

201 Our results provide compelling evidence for the existence of a membrane-bound  
202 receptor for sperm TMEM95 on eggs. Although the receptor has yet to be identified, our  
203 structural and site-directed mutagenesis studies identify a putative receptor-binding site  
204 on TMEM95. This region has a solvent-accessible surface area of  $\sim 1,200 \text{ \AA}^2$ ,  
205 comparable to protein surfaces that mediate many protein-protein interactions (14, 15).  
206 We envision that the TMEM95 receptor is a membrane protein with a negatively  
207 charged region on its ectodomain surface. Nevertheless, we cannot rule out potential  
208 non-protein receptor candidates with electrostatic negative properties on the egg  
209 surface, such as phospholipids and glycans.

210 The bivalent TMEM95-Fc protein introduced here may be a useful reagent to  
211 facilitate the identification of the egg receptor of TMEM95. As cell surface interactions  
212 between membrane-bound proteins are often transient and dynamic (2, 16), the avidity  
213 of a bivalent protein could serve to stabilize the potentially weak interaction of TMEM95  
214 with its receptor. TMEM95-Fc could therefore be used as a bait for the egg receptor, for  
215 example, for co-immunoprecipitation of mammalian eggs (*e.g.*, (17)), or for screening  
216 cultured cells expressing an egg cDNA library (*e.g.*, (2)).

217

### 218 **Potential roles of TMEM95 in membrane fusion**

219 The TMEM95 antibodies used in this study do not ablate binding of TMEM95 to  
220 hamster eggs. How would the non-blocking antibodies of TMEM95 inhibit sperm-egg  
221 fusion? One possibility is that TMEM95 undergoes structural changes that are important

222 for membrane fusion. Should sperm-egg fusion be accompanied by changes of  
223 TMEM95 in protein conformation or oligomeric state, the antibodies raised here against  
224 a defined conformation of TMEM95 may trap TMEM95 in a pre-fusion, monomeric state.  
225 Notably, early studies have suggested essential structural changes for IZUMO1 (*e.g.*,  
226 rearrangement of disulfides, protein dimerization) during sperm-egg membrane fusion  
227 (12, 18, 19).

228         Alternatively, or in addition, TMEM95 may assemble into a complex with other  
229 sperm proteins, such as a membrane fusogen. Antibody binding to TMEM95 could  
230 affect these events and explain the inhibitory results. Additionally, these antibodies  
231 might create steric hinderance which could interfere with membrane fusion (note,  
232 however, that an anti-IZUMO1 IgG, Mab125, does not block sperm-egg fusion, (20)).

233         Taken together, we conceptualize that sperm-egg membrane fusion involves  
234 pairwise cell surface interactions (Fig. 6). Sperm IZUMO1 binds egg JUNO, which  
235 mediates gamete adhesion, and a receptor-mediated interaction of sperm TMEM95 to  
236 the egg takes place; membrane fusion occurs thereafter. We anticipate additional  
237 analogous, yet to be identified, interactions between sperm proteins and their specific  
238 egg receptors.

239         In summary, our results suggest that human sperm TMEM95 likely plays a direct  
240 role in membrane fusion with eggs. Future work is needed to rule out indirect effects of  
241 TMEM95 antibodies that inhibit fusion while not blocking sperm-egg binding. More  
242 broadly, our work takes steps towards fully understanding the molecular interactions of  
243 the fertilization complex and has implications for the development of infertility treatments  
244 and contraceptives.

## 245 **Materials and methods**

246 Additional information is provided in *SI Appendix, SI Materials and Methods*.

247

### 248 **Immunofluorescence microscopy of hamster eggs**

249 Sexually mature female Syrian golden hamsters (Japan SLC Inc.) (approved by the  
250 Animal Care and Use Committee of the Research Institute for Microbial Diseases,  
251 Osaka University #28-4-2) were superovulated by peritoneal injection of pregnant mare  
252 serum gonadotropin and human coagulating gland (20 units for each; ASKA  
253 Pharmaceutical). Cumulus-oocyte complexes were extracted from the oviductal ampulla  
254 and treated with 1 mg/mL collagenase to remove the cumulus cells and zona pellucida,  
255 which yields zona-free eggs. These zona-free eggs were incubated with 200 nM Fc-  
256 fusion proteins in Biggers-Whitten-Whittingham (BWW) medium for 1 h and then stained  
257 with goat anti-human IgG Fc antibody DyLight 488 (Invitrogen) at a dilution of 1:50 for 1  
258 h at 37 °C, 5% CO<sub>2</sub>. The eggs were imaged under a Keyence BZ-X810 microscope.

259

### 260 **Protein crystallization of TMEM95**

261 Native TMEM95 proteins were crystallized at room temperature in a sitting-drop vapor  
262 diffusion system. 350 nL of 6.8 mg/mL protein was mixed with 350 uL of a reservoir  
263 solution of 150 mM NaCl, 20 mM HEPES pH 7.3, 30 mM CaCl<sub>2</sub>, 2% (w/v) PPG-P400,  
264 and 22% (w/v) PEG 3,350, over 80 uL of reservoir solution. Native crystals were  
265 supplemented with 20% (w/v) PEG 400 before cryo-cooling in liquid nitrogen. For multi-  
266 wavelength anomalous diffraction, crystals were grown in 150 mM NaCl, 20 mM HEPES  
267 pH 7.3, 10 mM CaCl<sub>2</sub>, 2% (w/v) PPG-P400, and 18% (w/v) PEG 3,350, and were

268 transferred to a solution supplemented with 500 mM SmCl<sub>3</sub> and incubated for ~5 min.  
269 The Sm<sup>3+</sup>-bound crystals were washed in a SmCl<sub>3</sub>-free reservoir solution, and cryo-  
270 protected with 20% PEG 400 for cooling in liquid nitrogen.

271

## 272 **Sperm penetration assay**

273 Sperm penetration assays were performed as previously described (10) with minor  
274 changes. Briefly, human semen from healthy donors, who had informed consent, was  
275 liquefied for 30 min at room temperature. The sperm were purified by discontinuous  
276 Percoll gradients (21) and incubated in BWW medium containing 2.5 μM calcium  
277 ionophore for 3 h at 37 °C, 5% CO<sub>2</sub>. The sperm were washed in fresh BWW medium  
278 and treated with monoclonal antibodies at 40 μg/mL for 1 h at 37 °C, 5% CO<sub>2</sub>. Zona-free  
279 hamster eggs were inseminated by the antibody-treated sperm at a density of 3×10<sup>6</sup>  
280 motile sperm per mL for 3 h at 37 °C, 5% CO<sub>2</sub>. The eggs were washed in fresh BWW,  
281 gently flattened by coverslips, and examined under a phase-contrast microscope.

282

## 283 **Accession number**

284 The coordinate and structure factor of human sperm TMEM95 ectodomain has been  
285 deposited in the RCSB Protein Data Bank under PDB ID code 7UX0. The structure is  
286 available immediately at <https://peterkimlab.stanford.edu>.

287

## 288 **Acknowledgement**

289 We thank members of the P.S.K., M.I., and P.V.L. laboratories, Dr. Jonathan Z.  
290 Long, and Dr. Masaru Okabe for discussion, Dr. Mirella Bucci for comments on the

291 manuscript, Gita Abhiraman and the laboratory of K. Christopher Garcia for protocols of  
292 baculovirus protein production, Dr. Daniel Fernandez of the Sarafan ChEM-H  
293 Macromolecular Structure Knowledge Center, and Silvia Russi of the Stanford  
294 Synchrotron Radiation Lightsource (SSRL) beam line 12-2 for X-ray crystallographic  
295 data collection. Use of the SSRL, SLAC National Accelerator Laboratory, is supported  
296 by the US Department of Energy (DOE), Office of Science, Office of Basic Energy  
297 Sciences under Contract DE-AC02-76SF00515. The SSRL Structural Molecular Biology  
298 Program is supported by the DOE, Office of Biological and Environmental Research and  
299 by a National Institutes of Health (NIH) grant P30GM133894.

300 We are grateful to the late Dr. Stuart Moss of the National Institute of Child  
301 Health and Human Development (NICHD). This work was supported by a NIH NICHD  
302 grant K99HD104924 (S.T.), Damon Runyon Cancer Research Foundation DRG-2301-  
303 17 (S.T.), the Ministry of Education, Culture, Sports, Science, and Technology, Japan  
304 Society for the Promotion of Science grants JP22K15103 (Y.L.), JP19H05750 (M.I.),  
305 and JP21H05033 (M.I.), a National Science Foundation Graduate Research Fellowship  
306 (W.M.S.), a Pew Biomedical Scholars Award (P.V.L.), the Global Consortium for  
307 Reproductive Longevity and Equality at the Buck Institute by the Bia-Echo Foundation  
308 (P.V.L.), the Virginia & D.K. Ludwig Fund for Cancer Research (P.S.K.), and Chan  
309 Zuckerberg Biohub (P.S.K.).

310

## 311 **Conflict of Interests**


312 The authors declare that there are no competing interests

## 313 Reference


- 314 1. N. Inoue, M. Ikawa, A. Isotani, M. Okabe, The immunoglobulin superfamily  
315 protein Izumo is required for sperm to fuse with eggs. *Nature* **434**, 234-238  
316 (2005).
- 317 2. E. Bianchi, B. Doe, D. Goulding, G. J. Wright, Juno is the egg Izumo receptor  
318 and is essential for mammalian fertilization. *Nature* **508**, 483-487 (2014).
- 319 3. H. Pausch *et al.*, A nonsense mutation in TMEM95 encoding a nondescript  
320 transmembrane protein causes idiopathic male subfertility in cattle. *PLoS Genet.*  
321 **10**, e1004044 (2014).
- 322 4. S. Zhang *et al.*, Detection of Bovine TMEM95 p.Cys161X Mutation in 13 Chinese  
323 Indigenous Cattle Breeds. *Animals (Basel)* **9** (2019).
- 324 5. T. Noda *et al.*, Sperm proteins SOF1, TMEM95, and SPACA6 are required for  
325 sperm-oocyte fusion in mice. *Proceedings of the National Academy of Sciences*  
326 *of the United States of America* 10.1073/pnas.1922650117 (2020).
- 327 6. I. Lamas-Toranzo *et al.*, TMEM95 is a sperm membrane protein essential for  
328 mammalian fertilization. *eLife* **9** (2020).
- 329 7. J. M. Bedford, H. D. Moore, L. E. Franklin, Significance of the equatorial segment  
330 of the acrosome of the spermatozoon in eutherian mammals. *Exp. Cell Res.* **119**,  
331 119-126 (1979).
- 332 8. R. Yanagimachi (1994) Mammalian fertilization. In. Knobil E, Neill J (editors). The  
333 Physiology of Reproduction. (New York: Raven Press).
- 334 9. M. R. Miller *et al.*, Unconventional endocannabinoid signaling governs sperm  
335 activation via the sex hormone progesterone. *Science* **352**, 555-559 (2016).
- 336 10. World Health Organization., *WHO laboratory manual for the examination and*  
337 *processing of human semen* (World Health Organization, Geneva, ed. 5th, 2010),  
338 pp. xiv, 271 p.

- 339 11. E. Bianchi, G. J. Wright, Cross-species fertilization: the hamster egg receptor,  
340 Juno, binds the human sperm ligand, Izumo1. *Philos Trans R Soc Lond B Biol*  
341 *Sci* **370**, 20140101 (2015).
- 342 12. H. Aydin, A. Sultana, S. Li, A. Thavalingam, J. E. Lee, Molecular architecture of  
343 the human sperm IZUMO1 and egg JUNO fertilization complex. *Nature* **534**, 562-  
344 565 (2016).
- 345 13. U. Ohto *et al.*, Structure of IZUMO1-JUNO reveals sperm-oocyte recognition  
346 during mammalian fertilization. *Nature* **534**, 566-569 (2016).
- 347 14. G. Schreiber, A. E. Keating, Protein binding specificity versus promiscuity. *Curr.*  
348 *Opin. Struct. Biol.* **21**, 50-61 (2011).
- 349 15. J. Chen, N. Sawyer, L. Regan, Protein-protein interactions: general trends in the  
350 relationship between binding affinity and interfacial buried surface area. *Protein*  
351 *Sci.* **22**, 510-515 (2013).
- 352 16. S. Tang, P. S. Kim, A high-affinity human PD-1/PD-L2 complex informs avenues  
353 for small-molecule immune checkpoint drug discovery. *Proceedings of the*  
354 *National Academy of Sciences of the United States of America* **116**, 24500-  
355 24506 (2019).
- 356 17. Y. Qu, D. Lu, H. Jiang, X. Chi, H. Zhang, EZH2 is required for mouse oocyte  
357 meiotic maturation by interacting with and stabilizing spindle assembly  
358 checkpoint protein BubR1. *Nucleic acids research* **44**, 7659-7672 (2016).
- 359 18. N. Inoue, Y. Hagihara, D. Wright, T. Suzuki, I. Wada, Oocyte-triggered  
360 dimerization of sperm IZUMO1 promotes sperm-egg fusion in mice. *Nat Commun*  
361 **6**, 8858 (2015).
- 362 19. N. Inoue, I. Wada, Monitoring dimeric status of IZUMO1 during the acrosome  
363 reaction in living spermatozoon. *Cell Cycle* **17**, 1279-1285 (2018).
- 364 20. N. Inoue *et al.*, Molecular dissection of IZUMO1, a sperm protein essential for  
365 sperm-egg fusion. *Development* **140**, 3221-3229 (2013).
- 366 21. S. L. Cafe, A. L. Anderson, B. Nixon, In vitro Induction and Detection of  
367 Acrosomal Exocytosis in Human Spermatozoa. *Bio Protoc* **10**, e3689 (2020).






**Fig. 1 TMEM95-Fc binds eggs.** Schematics of the Fc fusion protein with a fluorescence-conjugated Fc antibody. Immuno-fluorescence (upper) and differential interference contrast composite images (lower) of zona-free hamster eggs with 200 nM of (A) Fc, (B) TMEM95-Fc, (C) IZUMO1-Fc, or (D) IZUMO1<sup>W148A</sup>-Fc. Green fluorescence was conferred by a DyLight 488-conjugated Fc antibody. Scale bars, 100  $\mu$ m. TMEM95-Fc and IZUMO1-Fc bind zona-free hamster eggs. See also *SI Appendix*, Fig. S1.




**Fig. 2 The structure of TMEM95 is homologous to IZUMO1.** (A) Overlay of ribbon and space-filling diagrams of TMEM95 with structural elements labeled. (B) Ribbon diagram of TMEM95 with disulfide linkages labeled in yellow texts (same in IZUMO1) or red texts (different in IZUMO1). Domain organizations of (C) TMEM95 and (D) IZUMO1 with cysteine positions labeled as yellow dots and disulfide linked in black (same in TMEM95 and IZUMO1) or red lines (different in TMEM95 and IZUMO1). TMEM95 shows homology to the N-terminus of IZUMO1. See also *SI Appendix*, Fig. S2.




**Fig. 3 A conserved area of TMEM95 is a putative receptor binding site. (A-B)**

Space-filling *CONSURF* models (21) of TMEM95 with  $\sim 180^\circ$  rotation with purple representing variable and white representing conserved. (C) Space-filling model of electrostatic surface potential generated by APBS (Adaptive Poisson-Boltzmann Solver) with blue representing positively charged and red representing negatively charged. (D) Ribbon diagram of the conserved area of TMEM95 showing the side chains of surface-exposed residues. (E-H) Immuno-fluorescence (upper) and differential interference contrast composite images (lower) of zona-free hamster eggs with 200 nM of (E) TMEM95-Fc, (F) TMEM95<sup>R70A</sup>-Fc, (G) TMEM95<sup>R73A</sup>-Fc, and (H) TMEM95<sup>R70A R73A</sup>-Fc. Green fluorescence by a DyLight 488-conjugated Fc antibody. Scale bars 50  $\mu\text{m}$ . Substitutions of the conserved arginine residues on the identified surface of TMEM95 ablate egg-binding activities. See also *SI Appendix*, Fig. S3.




**Fig. 4 Antibodies detect the expression of TMEM95 in human sperm. (A, D)**

Bi-layer interferometric traces of sensor immobilized (A) TMEM95-Fc binding to 200 nM of TMEM95 antibodies 3A01 IgG and 6B08 IgG or (D) IZUMO1-Fc binding to IZUMO1 antibodies 4E04 IgG and 6F02 IgG, with association for 2 min and dissociation for 2 min. (B, E) Summary in a heat map of antibody competition (B) of 3A01 IgG and 6B08 IgG to sensor immobilized TMEM95-Fc and (E) of 4E04 IgG and 6F02 IgG to sensor immobilized IZUMO1-Fc. (C) Human sperm lysates without or with PNGaseF treatments. Western blots were performed using non-heat-denatured, non-reduced sperm lysates by a primary antibody of 10 µg/mL anti-TMEM95 3A01 IgG, and a secondary HRP-conjugated anti-mouse antibody. TMEM95 is expressed and N-linked glycosylated in human sperm. See also *SI Appendix*, Figs. S4 and S5.



**Fig. 5 TMEM95 antibodies impair sperm-egg fusion.** (A-D) Representative images showing binding of human sperm to zona-free hamster eggs (A) untreated or treated with 40  $\mu\text{g}/\text{mL}$  of (B) anti-IZUMO1 Fab 6F02, (C) anti-TMEM95 Fab 3A01, or (D) anti-TMEM95 Fab 6B08. (E) Summary of the numbers of bound human sperm per zona-free hamster eggs (mean  $\pm$  SEM), untreated  $77.4 \pm 7.5$  ( $N = 14$ ), anti-IZUMO1 Fab 6F02  $0 \pm 0$  ( $N = 10$ ), anti-TMEM95 3A01 Fab  $81.8 \pm 9.4$  ( $N = 10$ , *n.s.*, not significant), and anti-TMEM95 6B08 Fab  $76.4 \pm 10.8$  ( $N = 10$ , *n.s.*, not significant). (F) Summary of the numbers of fused human sperm per zona-free hamster eggs (mean  $\pm$  SEM), untreated  $9.1 \pm 0.7$  ( $N = 14$ ), anti-IZUMO1 Fab 6F02  $0 \pm 0$  ( $N = 10$ ), anti-TMEM95 3A01 Fab  $4.1 \pm 0.9$  ( $N = 10$ ,  $p = 0.0002$ ), and anti-TMEM95 6B08 Fab  $3.4 \pm 0.6$  ( $N = 10$ ,  $p < 0.0001$ ). TMEM95 antibodies do not block sperm-egg binding but impair sperm-egg fusion. See also *SI Appendix*, Fig. S6.



**Fig. 6 Model of sperm-egg binding and fusion.** Illustration of membrane fusion of sperm and an egg and pairwise protein-protein interactions: sperm IZUMO1 (blue) binds egg JUNO (pink) and a receptor (orange)-mediated interaction of sperm TMEM95 (green) to the egg takes place; membrane fusion occurs thereafter.

## Supplementary Information for

### Human sperm TMEM95 binds eggs and facilitates membrane fusion

Shaogeng Tang, Yonggang Lu, Will M. Skinner, Mrinmoy Sanyal,

Polina V. Lishko, Masahito Ikawa, Peter S. Kim

Peter S. Kim, Email: [kimpeter@stanford.edu](mailto:kimpeter@stanford.edu),

Masahito Ikawa, Email: [ikawa@biken.osaka-u.ac.jp](mailto:ikawa@biken.osaka-u.ac.jp)

### This PDF file includes:

#### SI Materials and Methods

**Fig. S1**, related to Fig. 1 Characterization of IZUMO1-Fc

**Fig. S2**, related to Fig. 2 JUNO is not a receptor of TMEM95

**Fig. S3**, related to Fig. 3 Characterization of TMEM95-Fc

**Fig. S4**, related to Fig. 4 Characterization of the TMEM95 antibodies

**Fig. S5**, related to Fig. 4 Characterization of the IZUMO1 antibodies

**Fig. S6**, related to Fig. 5 TMEM95 antibodies impair sperm-egg fusion

**Table S1** Crystallographic data collection and refinement statistics

**Table S2** Summary of the TMEM95 and IZUMO1 monoclonal antibodies

**Table S3** Plasmids and protein sequences used in this study

#### SI References

## SI Materials and Methods

### Expression and purification of the Fc-fusion proteins

The cDNAs encoding human TMEM95 (residues 1-145) or human IZUMO1 (residues 1-255) were subcloned into a pADD2 vector that carries a C-terminal fusion of a TEV protease cleavage site, a human IgG1 Fc, an Avi tag, and a hexa-histidine tag (*SI Appendix*, Table S3). The recombinant Fc fusion proteins were overexpressed by transient transfection of HEK293F cells (ThermoFisher) cultured at 37 °C, 8% CO<sub>2</sub>. TMEM95-Fc was purified by Ni-NTA affinity purification (Invitrogen), followed by anion exchange using an AKTA pure system by a Mono Q 5/50 GL (Cytiva). IZUMO1-Fc was purified by Protein-A affinity purification using a MabSelect Prism (Cytiva), followed by anion exchange using a Mono Q 5/50 GL. Purified proteins were stored in a buffer of 150 mM NaCl, 20 mM HEPES pH 7.4.

Tagless IZUMO1 proteins were obtained from IZUMO1-Fc through TEV (Sigma-Aldrich) cleavage overnight at 4 °C. Undigested proteins and the histidine tagged TEV proteases were removed by a MabSelect Prism followed by a HisTrap excel (Cytiva). Tagless IZUMO1 was further purified by gel filtration with a Superdex 200 Increase 10/300 GL (Cytiva) in a buffer of 150 mM NaCl, 20 mM HEPES pH 7.4.

### Protein expression and purification of JUNO

The cDNA encoding human JUNO (residues 20-227) was subcloned into a baculoviral vector pACgp67a that carries a signal sequence of MVSAIVLYVLLAAAHSFAFA and C-terminal hexa-histidine tag (*SI Appendix*, Table S3). Baculovirus was generated from Sf9 cells (ThermoFisher) by a co-transfection of pACgp67a and the BestBac Linearized



Baculovirus DNA (Expression Systems). Passage one baculovirus was tittered and used for infecting HighFive cells (ThermoFisher) cultured at 27 °C. ~3 days post infection, the conditioned media were harvested and mixed with NiCl<sub>2</sub>, CaCl<sub>2</sub>, and Tris pH 8.0 to a final concentration of 1 mM, 5 mM, and 100 mM, respectively. After centrifugation, the JUNO-His<sub>6</sub> proteins was purified by Ni-NTA affinity purification from the resulting supernatant, followed by gel filtration with a Superdex 200 Increase 10/300 GL in a buffer of 150 mM NaCl, 20 mM HEPES pH 7.4.

### **Biolayer interferometry**

An Octet RED96 system (Pall ForteBio) was employed for protein-protein interaction assays in a buffer of 150 mM NaCl, 20 mM HEPES pH 7.4, 0.1% bovine serum albumin, and 0.05% Tween 20 at 29 °C under a shaking speed of 1,000 rpm.

Biotinylated TMEM95-Fc or IZUMO1-Fc proteins were loaded onto Streptavidin biosensors (Sartorius). After loading the biosensors were baselined, associated in defined concentrations of analytes, and dissociated in the buffer with no analytes. Baseline-corrected binding traces were plotted and analyzed using GraphPad Prism 9.

### **Differential scanning fluorimetry**

A Prometheus NT.48 (NanoTemper) was employed for nanoscale differential scanning fluorimetry (NanoDSF). Protein samples were loaded into capillaries and subject to a temperature from 20 to 95 °C at a heating rate of 1 °C/min. Intrinsic fluorescence at 350 nm and 330 nm was recorded as a function of temperature. Thermal melting profiles

were plotted using the first derivative of the ratio ( $F_{350\text{ nm}}/F_{330\text{ nm}}$ ). Melting temperatures were calculated by the instrument and represented peaks in the thermal melting curves.

### **Protein purification of TMEM95**

The cDNA encoding human TMEM95 (residues 17-138) was subcloned into a pADD2 vector. The N-terminus of TMEM95 was fused to a signal sequence of MRMQLLLLLIALSLALVTNS and the C-terminus to a C-tag of EPEA (*SI Appendix*, Table S3). Recombinant TMEM95 proteins were overexpressed in HEK293F cells by transient transfection. Affinity purification was performed using the CaptureSelect C-tagXL affinity matrix (ThermoFisher). The eluate was purified by cation exchange by a Mono S 5/50 GL (Cytiva), followed by gel filtration with a Superdex 200 Increase 10/300 GL in a buffer of 150 mM NaCl, 20 mM HEPES pH 7.4. Size exclusion with multiangle light scattering was performed on an Agilent 1260 Infinity II high performance liquid chromatography coupled with Wyatt detectors for light scattering (miniDAWN) and refractive index (Optilab).

### **X-ray crystallography**

X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) beam line 12-2 of SLAC National Accelerator Laboratory. For the Sm<sup>3+</sup>-bound crystal, multi-wavelength anomalous diffraction data were collected at wavelengths 1.694 Å (peak), 1.137 Å (remote), and 1.695 Å (inflection). For the native crystal, the diffraction data were collected at 0.979 Å wavelength to 1.50 Å resolution. All diffraction data were processed using *autoPROC* (1). The TMEM95 ectodomain structure was

solved by experimental phasing using *AutoSol* in *Phenix* (2). An initial model containing 110 amino acids and two  $\text{Sm}^{3+}$  ions were obtained using *AutoBuild* and was subsequently applied to the native X-ray dataset by molecular replacement using *Phaser*. Model refinement and density modification were performed in *Phenix*. Model building was performed using *Coot* (3). Structural illustrations were generated with *PyMOL*.

### **Evolutionary conservation by *CONSURF***

The protein sequence of human TMEM95 was input as a query sequence for a protein BLAST search using blastp. The top 150 results from were filtered manually and ortholog-unique sequences were subjected for alignment by MAFFT. The multiple sequence alignment and the TMEM95 structure were used as input in the *CONSURF* server (4). The overall conservation scores from 1 to 9 were calculated using the Bayesian methods for each amino acid and were mapped onto the TMEM95 structure in a color-coordinated fashion as shown in Fig. 3.

### **Generation of mouse hybridomas**

Five female BALB/c mice (Jackson Laboratory) aged ~8 weeks (approved by Stanford University Administrative Panel on Laboratory Animal Care, APLAC 33984) were immunized with 10  $\mu\text{g}$  purified protein of TMEM95 (residues 17-138) in 100  $\mu\text{L}$  of 150 mM NaCl, 20 mM HEPES pH 7.4, adjuvanted with 10  $\mu\text{g}$  Quil-A (Invivogen) and 10  $\mu\text{g}$  monophosphoryl lipid A (InvivoGen). Mice were boosted at days 21, 43, 64, and 86. At day 90, a spleen of one mouse was disaggregated into a single-cell suspension for

hybridoma generation following the manufacturer's procedures (Stemcell technologies). Briefly, splenocytes were purified and fused with Sp2/0-Ag14 cells (ATCC) using polyethylene glycol. Hybridomas were cultured in 96-well plates with a selection medium containing hypoxanthine, aminopterin, and thymidine. ~14 days after recovery, the conditioned media were screened for binding to TMEM95 by ELISA. TMEM95-binding-positive cells were sorted as single cells in 96-well plates using a SONY SH800S. ~14 days after recovery, the conditioned media were screened, and the selected TMEM95-positive clones were expanded for antibody sequencing (Genscript Biotech, Table S2). Similarly, five mice were immunized with IZUMO1 (residues 22-255) and boosted at days 21, 43, 61, and 96. At day 100, a spleen from one mouse was used for hybridoma generation.

### **Antibody production and purification**

Hybridomas producing the TMEM95 and IZUMO1 antibodies were cultured in ClonaCell-HY Medium E (Stemcell technologies) and subsequently adapted to serum-free AOF Expansion Medium (Stemcell technologies) for 5-7 days at 37 °C, 5% CO<sub>2</sub>. The IgG in the conditioned AOF media was harvested from the supernatants and subjected for affinity purification by a HiTrap Protein G HP (Cytiva) and gel filtration with a Superdex 200 Increase 10/300 GL in a buffer of 150 mM NaCl, 20 mM HEPES pH 7.4.

The cDNAs encoding the heavy and light chains of the TMEM95 and IZUMO1 antibody Fab were subcloned into a pVRC vector (*SI Appendix*, Table S3). The Fabs were produced in HEK293F cells by transient transfection at 37 °C, 8% CO<sub>2</sub>, and


purified from the supernatants of the conditioned media by a HiTrap Protein G HP, followed by gel filtration with a Superdex 200 Increase 10/300 GL in a buffer of 150 mM NaCl, 20 mM HEPES pH 7.4. All antibodies were concentrated to 1.0 mg/mL, supplemented with 10% glycerol, and aliquoted for long-term storage at -80 °C.

### **Human sperm isolation and western blotting**

The experimental procedures utilizing human derived samples in Fig. 4 and *SI Appendix* Figs. S4 and S5 were approved by the Committee on Human Research at the University of California, Berkeley, IRB protocol 2013-06-5395. Purified human sperm (5) were lysed in a buffer of 150 mM NaCl, 50 mM Tris pH 7.4, 1% Triton X-100, 0.5% Sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 10% (v/v) glycerol, and Halt protease inhibitors (ThermoFisher). The protein concentrations of the whole cell lysates were estimated by a Bradford assay (BioRad) using bovine serum albumin as a standard. The lysates were stored at 4 °C in a non-reducing condition before loaded onto an SDS-PAGE gel for electrophoresis. 15 µg of lysates and 10 µg/mL of TMEM95 antibodies were used for the detection of TMEM95; 7 µg of lysates and 2 µg/mL of IZUMO1 antibodies were used for the detection of IZUMO1. A secondary antibody of HRP-conjugated goat anti-mouse IgG (BioLegend) was used for immunoblotting. PNGaseF treatment was performed under non-reducing conditions following the manufacturer's instructions (NEB).

## SI Reference


1. C. Vonrhein *et al.*, Data processing and analysis with the autoPROC toolbox. *Acta crystallographica. Section D, Biological crystallography* **67**, 293-302 (2011).
2. D. Liebschner *et al.*, Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr D Struct Biol* **75**, 861-877 (2019).
3. P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics. *Acta crystallographica. Section D, Biological crystallography* **60**, 2126-2132 (2004).
4. H. Ashkenazy *et al.*, ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. *Nucleic acids research* **44**, W344-350 (2016).
5. W. M. Skinner, N. Mannowetz, P. V. Lishko, N. R. Roan, Single-cell Motility Analysis of Tethered Human Spermatozoa. *Bio Protoc* **9** (2019).



**Fig. S1**, related to Fig. 1, Characterization of IZUMO1-Fc. (A) Coomassie-blue stained SDS-PAGE gel of Fc, IZUMO1<sup>WT</sup>-Fc, IZUMO1<sup>W148A</sup>-Fc, and TMEM95-Fc proteins under non-reducing (left) or reducing conditions (right). (B) Cartoon schematic and ribbon diagram (PDB ID: 5F4E) of the IZUMO1-JUNO complex showing the side chain of W148 of IZUMO1 mediates interactions with JUNO. (C-D) NanoDSF thermal melting profiles of (C) Fc, IZUMO1<sup>WT</sup>-Fc, IZUMO1<sup>W148A</sup>-Fc, and (D) JUNO proteins. (E) Quantification of fluorescence intensities (a.u., arbitrary unit; \*\*\*\*,  $p < 0.0001$ , n.s. not significant) of Fc, TMEM95-Fc, IZUMO1<sup>WT</sup>-Fc, and IZUMO1<sup>W148A</sup>-Fc on eggs shown in


Figure 1. (F-G) Biolayer interferometric traces of sensor immobilized (F) IZUMO1-Fc or (G) IZUMO1<sup>W148A</sup>-Fc binding JUNO of 300 nM, 100 nM, 33 nM, 11 nM, and 3.7 nM, with association for 2 min and dissociation for 2 min. (H) List of binding constants of IZUMO1-Fc with JUNO calculated from traces in (F).






**Fig. S2**, related to Fig. 2, JUNO is not a receptor for TMEM95. (A) Ribbon diagram overlay with a  $2F_{\text{obs}} - F_{\text{calc}}$  electron density map surrounding the  $\text{Sm}^{3+}$  ions between two TMEM95 protomers (green and cyan) in the crystal lattice solved by multi-wavelength X-ray anomalous diffraction. (B) Multiple sequence alignment of the  $\alpha 1$  region of TMEM95 orthologs with conserved cysteines highlighted in yellow. (C-D) Ribbon diagrams overlay with a space-filling model of (C) the IZUMO1-JUNO complex (PDB ID: 5F4E), (D) the TMEM95-superimposed JUNO complex, where the N-glycan of TMEM95

causes a clash with JUNO. (E) Ribbon diagram overlay with a  $2F_{\text{obs}}-F_{\text{calc}}$  composite omit (10%) electron density map of the N117 side chain and its linked glycan. (F) Multiple sequence alignment of the  $\beta$ -hairpin of TMEM95 orthologs with conserved cysteines highlighted in yellow and the asparagine in purple. (G) Coomassie-blue stained SDS-PAGE gel of TMEM95-Fc treated without or with PNGaseF under non-reducing (left) or reducing (right) conditions. (H) Biolayer interferometric traces of sensor immobilized TMEM95-Fc treated without or with PNGaseF binding to JUNO of 300 nM, with association for 2 min and dissociation for 2 min.




**Fig. S3**, related to Fig. 3, Characterization of TMEM95-Fc. (A) Coomassie-blue stained SDS-PAGE gel of TMEM95-Fc, TMEM95<sup>R70A</sup>-Fc, TMEM95<sup>R73A</sup>-Fc, and TMEM95<sup>R70A R73A</sup>-Fc proteins under non-reducing (left) or reducing conditions (right). (B) NanoDSF thermal melting profiles of TMEM95-Fc, TMEM95<sup>R70A</sup>-Fc, TMEM95<sup>R73A</sup>-Fc, and TMEM95<sup>R70A R73A</sup>-Fc proteins. (C) Quantified green fluorescence intensities (a.u., arbitrary unit; \*\*\*\*,  $p < 0.0001$ ) of TMEM95-Fc, TMEM95<sup>R70A</sup>-Fc, TMEM95<sup>R73A</sup>-Fc, and TMEM95<sup>R70A R73A</sup>-Fc proteins on eggs shown in Figure 3.



**Fig. S4**, related to Fig. 4, Characterization of the TMEM95 antibodies. (A) Size exclusion and multiangle light scattering of the TMEM95 protein showing a monodispersed peak with a calculated molecular weight of 18.4 kDa, as an expected monomer in solution. (B) NanoDSF thermal melting profile of the TMEM95 protein used for protein crystallization and mouse immunization. (C) Schedule of mouse immunization using the TMEM95 protein. (D) Bi-layer interferometric traces of sensor


immobilized TMEM95-Fc binding to 3A01 Fab or 6B08 Fab at concentrations of 600 nM, 200 nM, 67 nM, 22 nM, and 7.4 nM, with association for 3 min and dissociation for 6 min. (E) Summary of binding constants of TMEM95-Fc with anti-TMEM95 3A01 Fab and 6B08 Fab calculated from traces in (D). (F) Western blots of non-heat-denatured, non-reduced human sperm lysates by a primary antibody of 10 µg/mL anti-TMEM95 3A01 IgG or 6B08 IgG, and a secondary HRP-conjugated anti-mouse antibody. (G) Immuno-fluorescence (upper) and differential interference contrast composite images (lower) of zona-free hamster eggs incubated with TMEM95-Fc that has been pre-bound to protein G purified pre-immune mouse IgG, anti-TMEM95 3A01 IgG, or 6B08 IgG. 2.5 µM TMEM95-Fc was mixed with 5 µM (0.75 mg/mL) IgG for 1 hour to form a complex of TMEM95-Fc and the antibody, and the mixture was added to the eggs at a final concentration of 200 nM TMEM95-Fc. Green fluorescence by a DyLight 488-conjugated Fc antibody. Scale bars 100 µm. (H) Biolayer interferometric traces of sensor-immobilized TMEM95-Fc, TMEM95<sup>R70A</sup>-Fc, TMEM95<sup>R73A</sup>-Fc, and TMEM95<sup>R70A R73A</sup>-Fc proteins binding to 200 nM of 3A01 IgG or 6B08 IgG, with association for 2 min and dissociation for 2 min.



**Fig. S5**, related to Fig. 4, Characterization of the IZUMO1 antibodies. (A) Size exclusion and multiangle light scattering of the IZUMO1 protein showing a monodispersed peak

with a calculated molecular weight of 30.8 kDa, as an expected monomer in solution.

(B) NanoDSF thermal melting profile of the IZUMO1 protein used for mouse immunization. (C) Schedule of mouse immunization of the IZUMO1 protein. (D) Biolayer interferometric traces of sensor immobilized IZUMO1-Fc binding to 4E04 Fab or 6F02 Fab at concentrations of 600 nM, 200 nM, 67 nM, 22 nM, and 7.4 nM, with association for 3 min and dissociation for 6 min. (E) Summary of binding constants of IZUMO1-Fc with anti-IZUMO1 4E04 Fab and 6F02 Fab calculated from traces in (D). (F) Western blots of non-heat-denatured, non-reduced human sperm lysates by a primary antibody of 2 µg/mL anti-IZUMO1 4E04 IgG or 6F02 IgG, and a secondary HRP-conjugated anti-mouse antibody. (G) Immuno-fluorescence (upper) and differential interference contrast composite images (lower) of zona-free hamster eggs incubated with IZUMO1-Fc that has been pre-bound to protein G purified pre-immune mouse IgG, anti-IZUMO1 4E04 IgG, or 6F02 IgG. 2.5 µM IZUMO1-Fc was mixed with 5 µM (0.75 mg/mL) IgG for 1 hour to form a complex of IZUMO1-Fc and the antibody, and the mixture was added to the eggs at a final concentration of 200 nM IZUMO1-Fc. Green fluorescence by a DyLight 488-conjugated Fc antibody. Scale bars, 100 µm. (H) Biolayer interferometric traces of sensor immobilized IZUMO1-Fc, or IZUMO1-Fc in complex with 4E04 IgG, 6F02 IgG binding to 300 nM JUNO, with association for 3 min and dissociation for 3 min. (I) Summary of antibody competition with the IZUMO1-Fc and JUNO interaction calculated from (H). (J) Biolayer interferometric traces of sensor-immobilized IZUMO1-Fc and IZUMO1<sup>W148A</sup>-Fc binding to 200 nM of 4E04 IgG or 6F02 IgG, with association for 2 min and dissociation for 2 min.



**Fig. S6**, related to Fig. 5, TMEM95 antibodies impair sperm-egg fusion. Representative images showing fusion of human sperm with zona-free hamster eggs (A) untreated or treated with 40  $\mu\text{g}/\text{mL}$  of (B) anti-IZUMO1 Fab 6F02, (C) anti-TMEM95 Fab 3A01, or (D) anti-TMEM95 Fab 6B08. Arrows indicating fused sperm with swollen sperm heads. Scale bars, 50  $\mu\text{m}$ . (E-G) Representative images showing binding of human sperm with



zona-free hamster eggs in the presence of 40  $\mu\text{g}/\text{mL}$  (E) pre-immune mouse IgG, (F) anti-IZUMO1 IgG 6F02, (G) anti-TMEM95 IgG 3A01 (left), or anti-TMEM95 IgG 6B08 (right) after 3 hours of insemination. Scale bars, 50  $\mu\text{m}$ . (H) Summary of the numbers of fused human sperm per zona-free hamster eggs in each group (mean  $\pm$  SEM), control  $12.9 \pm 1.7$  ( $N = 10$ ), anti-IZUMO1 6F02  $0 \pm 0$  ( $N = 10$ ), anti-TMEM95 3A01  $3.3 \pm 0.8$  ( $N = 8$ ,  $p < 0.001$ ), and anti-TMEM95 6B08  $4.0 \pm 1.1$  ( $N = 9$ ,  $p < 0.01$ ). Representative images showing fusion of human sperm with zona-free hamster eggs in the presence of 40  $\mu\text{g}/\text{mL}$  (I) pre-immune mouse IgG, (J) anti-IZUMO1 IgG 6F02, (K) anti-TMEM95 IgG 3A01, and (L) anti-TMEM95 IgG 6B08. Arrows indicating fused sperm with swollen sperm heads. Scale bars, 50  $\mu\text{m}$ .

**Table S1 Crystallographic data collection and refinement statistics**

	Human TMEM95 ectodomain			
	Native	Multi-wavelength anomalous diffraction		
		Peak	Remote	Inflection
<b>PDB ID</b>	7UX0			
<b>Wavelength, Å</b>	0.97946	1.69457	1.13743	1.69515
<b>Resolution range, Å</b>	36.01 - 1.50 (1.52 - 1.50)	39.01 - 2.10 (2.14 - 2.10)	29.09 - 1.97 (2.00 - 1.97)	39.02 - 2.12 (2.15 - 2.12)
<b>Space group</b>	<i>P</i> 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	<i>P</i> 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	<i>P</i> 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	<i>P</i> 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>
<b>Unit cell</b>	39.53 43.11 72.02 90 90 90	39.30 43.22 78.01 90 90 90	39.32 43.25 78.09 90 90 90	39.31 43.23 78.03 90 90 90
<b>Total reflections</b>	258299 (13130)	90875 (3275)	109780 (6269)	92437 (3364)
<b>Unique reflections</b>	20505 (1004)	7810 (370)	8952 (476)	7866 (365)
<b>Multiplicity</b>	12.6 (13.1)	11.6 (8.9)	12.3 (13.2)	11.8 (9.2)
<b>Completeness, %</b>	99.7 (100.0)	95.7 (92.7)	90.1 (100.0)	98.0 (93.8)
<b>Mean <math>I/\sigma(I)</math></b>	12.3 (2.2)	14.20 (2.4)	12.10 (2.2)	14.1 (2.1)
<b><math>R_{merge}</math></b>	0.148 (1.803)	0.188 (0.922)	0.184 (1.641)	0.173 (1.137)
<b><math>CC_{1/2}</math></b>	0.997 (0.855)	0.998 (0.882)	0.998 (0.834)	0.998 (0.786)
<b><math>R_{work}</math></b>	0.223			
<b><math>R_{free}</math></b>	0.251			
<b>Number of non-hydrogen atoms</b>	1133			
macromolecules	985			
solvent	89			
<b>Protein residues</b>	115			
<b>RMS(bonds), Å</b>	0.007			
<b>RMS(angles), °</b>	1.03			
<b>Ramachandran favored, %</b>	98.20			
<b>Ramachandran outliers, %</b>	0.00			
<b>Clashscore</b>	3.90			
<b>Average B-factor</b>	29.95			
macromolecules	28.69			
solvent	36.35			

Statistics for the highest-resolution shell are shown in parentheses.

**Table S2 Summary of the TMEM95 and IZUMO1 monoclonal antibodies**

Antigen	Antibody	Isotype	V-gene	D-gene	J-gene	CDR1	CDR2	CDR3	
TMEM95	3A01	V <sub>H</sub>	IgG1	IGHV5-9-4*01	IGHD1-1*01	IGHJ4*01	NYVMS	EISTYGRYTFYPDSVTG	RDYYGSSSVMDY
		V <sub>L</sub>	Kappa	IGKV4-57-1*01		IGKJ1*01	RASSSVSSSSLH	STSNLAS	QQYSGYPLT
	6B08	V <sub>H</sub>	IgG1	IGHV5-6*01 IGHV5-6-1*01	N/A	IGHJ4*01	TYGMS	TISFYGHTTYYPDILKG	EDYDAMDY
		V <sub>L</sub>	Kappa	IGKV9-120*02		IGKJ2*01	RASQDIGSNLN	ATSSLDS	LQYAIFPYT
IZUMO1	4E04	V <sub>H</sub>	IgG1	IGHV2-6-5*01	IGHD2-1*01 IGHD2-10*01 IGHD2-10*02	IGHJ2*01	DFGIS	LIWGGGNTYYNSALKS	HGRFGNTPDY
		V <sub>L</sub>	Kappa	IGKV1-110*01		IGKJ1*01	TSGQSLVQSNGNTYLH	KVSNRFS	SQSTRFPWT
	6F02	V <sub>H</sub>	IgG1	IGHV3-1*02	IGHD2-4*01 IGHD2-9*02	IGHJ2*01	SAYVWH	YIQYSGSTNYNPSLTS	AMITRGYFDY
		V <sub>L</sub>	Kappa	IGKV14-111*01		IGKJ4*01	KASQDSNSYLS	GANRLVD	LQYDEFPT

## Table S3 Plasmids and protein sequences used in this study

### Plasmids for protein expression from HEK293F transient transfection

Plasmid	Description & encoded protein sequence
pST980	pADD2 Fc MGWSCIIILFLVATATGVHSENLVFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGK
pST1392	pADD2 Fc-Avi-His6 MGWSCIIILFLVATATGVHSENLVFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHEGHHHHHH
pST1359	pADD2 TMEM95-Fc-Avi-His6 MWRLALGGVFLAAQACVFCRLPAHDLGRLARLCSQMEARQKECGASPDFSAFALDEVSMNKVTEKTHRVLRVMEIKEAVSSLPSYWSWLRKTKLPEYTREALCPPACRGSTTLVNCSTCKGTEVSCWPRKRCFPGSQDLWEAKENLYFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHEGHHHHHHH
pST1094	pADD2 IZUM01-Fc MGPHTLLCAALAGCLLPAEGCVICDPSVVLALKSLEKDYLPGHLDAKHHKAMMERVENAVKDFQELSLNEDAYMGVVDEATLQKGSWSLLKDLKRITDSVDKGLFVKELFWMLHLQKETFFATYVARFQKEAYCPNKCGVMLQTLIWCNCKKEVHACRKS YDCGERNVEVPQMEDMILDCELNWHQASEGLTDYSFYRVWGNNTETLVSKGKEATLTKPMVGPEDAGSYRCELGSVNSSPATI INFHVTVLPKENLYFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGK
pST1373	pADD2 IZUM01-Fc-Avi-His6 MGPHTLLCAALAGCLLPAEGCVICDPSVVLALKSLEKDYLPGHLDAKHHKAMMERVENAVKDFQELSLNEDAYMGVVDEATLQKGSWSLLKDLKRITDSVDKGLFVKELFWMLHLQKETFFATYVARFQKEAYCPNKCGVMLQTLIWCNCKKEVHACRKS YDCGERNVEVPQMEDMILDCELNWHQASEGLTDYSFYRVWGNNTETLVSKGKEATLTKPMVGPEDAGSYRCELGSVNSSPATI INFHVTVLPKENLYFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHEGHHHHHHH
pST1710	pADD2 IZUM01-Fc-Avi-His6 W148A MGPHTLLCAALAGCLLPAEGCVICDPSVVLALKSLEKDYLPGHLDAKHHKAMMERVENAVKDFQELSLNEDAYMGVVDEATLQKGSWSLLKDLKRITDSVDKGLFVKELFWMLHLQKETFFATYVARFQKEAYCPNKCGVMLQTLIACKNCKKEVHACRKS YDCGERNVEVPQMEDMILDCELNWHQASEGLTDYSFYRVWGNNTETLVSKGKEATLTKPMVGPEDAGSYRCELGSVNSSPATI INFHVTVLPKENLYFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGKGSGLNDIFEAQKIEWHEGHHHHHHH
pST1557	pADD2 TMEM95-Ctag MRMQLLLLIALLSLALVTNSCVFCRLPAHDLGRLARLCSQMEARQKECGASPDFSAFALDEVSMNKVTEKTHRVLRVMEIKEAVSSLPSYWSWLRKTKLPEYTREALCPPACRGSTTLVNCSTCKGTEVSCWPRKRCFPGSEPEA

pST1704	pADD2 TMEM95-Fc-Avi-His6 R70A MWRLALGGVFLAAAQACVFCRLPAHDLSGRLARLCSQMEARQKECGASPDFSAFALDEVSMNKVTEKTHA VLRVMEIKEAVSSLSYWSWLRKTKLPEYTREALCPPACRGSTTLINCSTCKGTEVSCWPRKRCFPGSQD LWEAKENLYFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK SRWQQGNVFSVMSVMEALHNHYTQKSLSLSPGKSGSLNDIFEAQKIEWHEGHHHHHH
pST1705	pADD2 TMEM95-Fc-Avi-His6 R73A MWRLALGGVFLAAAQACVFCRLPAHDLSGRLARLCSQMEARQKECGASPDFSAFALDEVSMNKVTEKTHR VLAVMEIKEAVSSLSYWSWLRKTKLPEYTREALCPPACRGSTTLINCSTCKGTEVSCWPRKRCFPGSQD LWEAKENLYFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK SRWQQGNVFSVMSVMEALHNHYTQKSLSLSPGKSGSLNDIFEAQKIEWHEGHHHHHH
pST1761	pADD2 TMEM95-Fc-Avi-His6 R70A R73A MWRLALGGVFLAAAQACVFCRLPAHDLSGRLARLCSQMEARQKECGASPDFSAFALDEVSMNKVTEKTHA VLAVMEIKEAVSSLSYWSWLRKTKLPEYTREALCPPACRGSTTLINCSTCKGTEVSCWPRKRCFPGSQD LWEAKENLYFQGGSGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK SRWQQGNVFSVMSVMEALHNHYTQKSLSLSPGKSGSLNDIFEAQKIEWHEGHHHHHH
pST1720	pVRC anti-TMEM95 3A01 IgG1 heavy chain MGWSCIIILFLVATATGVHSEVQLVESGGDLVLRPGGSLKLSVVSFGFAFSNYVMSWVRQSPPEKRLWVAEI STYGRYTFYPDSVTGRFTISRDNKNTLFLFEMSSLRSEDSAMYCARRDYGGSSVMDYWGQGTSVIVSS AKTTPPSVYPLAPGSAQAQTNMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV PSSTWVPSVTCNVAHPASSTKVDKIKVPRDCGCKPCICTVPEVSSVFI FPPKPKDVLITITLTPKVTCVV VDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIE KTISKTKGRPKAPQVYTI PPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGS YFVYSKLVQKSNWEAGNTFTCSVLHEGLHNHHTKSLSHSPGK
pST1721	pVRC anti-TMEM95 3A01 Fab heavy chain MGWSCIIILFLVATATGVHSEVQLVESGGDLVLRPGGSLKLSVVSFGFAFSNYVMSWVRQSPPEKRLWVAEI STYGRYTFYPDSVTGRFTISRDNKNTLFLFEMSSLRSEDSAMYCARRDYGGSSVMDYWGQGTSVIVSS AKTTPPSVYPLAPGSAQAQTNMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTV PSSTWVPSVTCNVAHPASSTKVDKIKVPRDC
pST1722	pVRC anti-TMEM95 3A01 light chain MGWSCIIILFLVATATGVHSENVLTQSPAIMSASPGKVTMPCRASSVSSSSSLHWYQKSGASPKLWIYS TSNLASGVPARFSGSGGTSYSLTITSVEAEDAATYYCQOYSGYPLTFGGGKLEIKADAAPTVISIFPPS SEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDQSKDSTYSMSSTLTLTKDEYERHNS YTCEATHKTSTSPIVKSFNRNEC
pST1723	pVRC anti-TMEM95 6B08 IgG1 heavy chain MGWSCIIILFLVATATGVHSEVQLVESGGDLVLRPGGSLKLSAASGFTFSTYGMWVRQTPDKRLEWVATI SFYGTHTYYPDILKGRFTISRDNKNTLYLQMSLKSSED TAMYFCAREDYDAMDYWGQGTSVTVSSAKTT PPSVYPLAPGSAQAQTNMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSST WPSETVTCNVAHPASSTKVDKIKVPRDCGCKPCICTVPEVSSVFI FPPKPKDVLITITLTPKVTCVVVDIS KDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTIS KTKGRPKAPQVYTI PPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVY SKLVNVOKSNWEAGNTFTCSVLHEGLHNHHTKSLSHSPGK
pST1724	pVRC anti-TMEM95 6B08 Fab heavy chain MGWSCIIILFLVATATGVHSEVQLVESGGDLVLRPGGSLKLSAASGFTFSTYGMWVRQTPDKRLEWVATI SFYGTHTYYPDILKGRFTISRDNKNTLYLQMSLKSSED TAMYFCAREDYDAMDYWGQGTSVTVSSAKTT PPSVYPLAPGSAQAQTNMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSST WPSETVTCNVAHPASSTKVDKIKVPRDC
pST1725	pVRC anti-TMEM95 6B08 light chain MGWSCIIILFLVATATGVHSDIQMTQSPSSLSASLGERVSLTCRASQDIGNLNWLQOEPDGTIKRLIYAT SSLDGVPKRFSGSRSGSDYSLTISSESEDFVDYYCLOYAIFPYTFGGGKLEIKADAAPTVISIFPPSS

	EQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDYSTYSMSSTLTLTKDEYERHNSY TCEATHKTSTSPIVKSFNRENC
pST1776	pVRC anti-IZUMO1 4E04 IgG1 heavy chain
	MGWSCIIILFLVATATGVHSDVQLKESGPGVLVAPSQSLSTCTVSGFSLTDFGISWIRQPPGKGLEWLGLI WGGGNTYYNSALKSRLSISKDNSKSQVFLKMNSLQDDTAMYYCAKHGRFGNTPDYWGQGTTLTVSSAKT TPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPS TWPSETVTCNVAHPASSTKVDDKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLITITLTPKVTCVVVDI SKDDPEVQFSWFVDDVEVHTAQTPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKT SKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFV YSKLNQKSNWEAGNTFTCSVLHEGLHNNHTEKSLSHSPGK
pST1777	pVRC anti-IZUMO1 4E04 Fab heavy chain
	MGWSCIIILFLVATATGVHSDVQLKESGPGVLVAPSQSLSTCTVSGFSLTDFGISWIRQPPGKGLEWLGLI WGGGNTYYNSALKSRLSISKDNSKSQVFLKMNSLQDDTAMYYCAKHGRFGNTPDYWGQGTTLTVSSAKT TPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPS TWPSETVTCNVAHPASSTKVDDKIVPRDC
pST1778	pVRC anti-IZUMO1 4E04 light chain
	MGWSCIIILFLVATATGVHSDVVMVTQTPLSLPLVSLGDQASFSCTSGQSLVQSNNTYLHWYLQKPGQSPKL LIYKVSNRFSVGPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTRFPWTFGGGKLEIKADAAPTVSI FPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDYSTYSMSSTLTLTKDEYE RHNSYTCEATHKTSTSPIVKSFNRENC
pST1779	pVRC anti-IZUMO1 6F02 IgG1 heavy chain
	MGWSCIIILFLVATATGVHSDVQLQESGPDLVKPSQSPSLTCTVTGYSITSAYVWHWIRQPPGKLEWGMGY IQYSGSTNYNPSLTSRISITRDTSKNQFFLKLKSVTTADTATYYCARAMITRGYFDYWQGTTLTVSSAK TTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPS STWPSETVTCNVAHPASSTKVDDKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLITITLTPKVTCVVVD ISKDDPEVQFSWFVDDVEVHTAQTPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKT ISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYF VYSKLNQKSNWEAGNTFTCSVLHEGLHNNHTEKSLSHSPGK
pST1780	pVRC anti-IZUMO1 6F02 Fab heavy chain
	MGWSCIIILFLVATATGVHSDVQLQESGPDLVKPSQSPSLTCTVTGYSITSAYVWHWIRQPPGKLEWGMGY IQYSGSTNYNPSLTSRISITRDTSKNQFFLKLKSVTTADTATYYCARAMITRGYFDYWQGTTLTVSSAK TTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPS STWPSETVTCNVAHPASSTKVDDKIVPRDC
pST1783	pVRC anti-IZUMO1 6F02 light chain
	MGWSCIIILFLVATATGVHSDIKMTQSPSSMYASLGERVITITCKASQDSNSYLSWIQQKPGKSPKTLIYGA NRLVDGVPSPRFSGSGSGQDYSLTISSEYEDMGFYCYCLOYDEFPTFGSGTKLETKADAAPTVSIFPPSS EQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDYSTYSMSSTLTLTKDEYERHNSY TCEATHKTSTSPIVKSFNRENC

### Plasmid for protein expression from baculovirus infection

Plasmid	Description & encoded protein sequence
pST1618	pACgp67a JUNO-His6
	MVSAIVLYVLLAAAHAHSFAGDELNLCMNAKHHKRVSPEDKLYEECIPWKDNACCTLTTSWEAHLDVD PLYNFSLFHCGLLMPGCRKHF IQAICFYECSPNLGPWIQPVGSLGWEVAPSGQGERVVNVPLCQEDCEEW WEDCRMSYTCCKSNWRGGWDWSQGNRCPKGAQCLPFSHYFPTPADLCEKTWSNSFKASPERRNSGRCLQK WFEPAQGNPNVAVARLFAGGHHHHHH